Is sotoracib (AMG510) a targeted drug or a chemotherapy drug?

Sotoracib (AMG510) is the first approved KRAS G12C inhibitor and a targeted drug that has been proven to provide durable clinical efficacy in patients with KRAS G12C mutated non-small cell lung cancer. As new targeted drugs are developed, the development of strategies to control resistance mechanisms is one of the main drivers of research, and KRAS inhibitors are being explored not only alone, but also in combination with other targeted therapies, chemotherapy, and immunotherapy.

Targeted drugs refer to drugs that treat cancer by specifically acting on specific molecules or signaling pathways in cancer cells. KRAS gene mutations play a crucial role in tumor development, and are particularly common in common cancers such as lung cancer. When the KRAS protein mutates, it remains activated, driving cancer cells to proliferate. Sotoracib was developed to combat this problem. As a first-generation KRAS G12C inhibitor, sotoraxib has extraordinary specificity and can accurately identify and act on tumor cells carrying KRAS G12C mutations, while maintaining no effect on normal KRAS protein, which greatly reduces the side effects of treatment.

Through a unique mechanism of action, sotorasiib tightly binds toKRAS G12C mutant protein, thereby effectively shutting down its activity. In this way, the signaling pathways closely related to the proliferation and survival of cancer cells are successfully blocked, achieving the purpose of inhibiting tumor growth. This achievement not only provides new hope for cancer patients who have long been difficult to obtain effective treatment due to KRAS mutations, but also marks a new stage in the field of targeted therapy.